T1	Participants 78 134	children with standard-risk acute lymphoblastic leukemia
T2	Participants 478 518	After remission induction, 2027 patients
T3	Participants 202 477	The Children's Cancer Group 1952 (CCG-1952) clinical trial studied the substitution of oral 6-thioguanine (TG) for 6-mercaptopurine (MP) and triple intrathecal therapy (ITT) for intrathecal methotrexate (IT-MTX) in the treatment of standard-risk acute lymphoblastic leukemia.
#1	AnnotatorNotes T3	Participants were those in this trial.
